ClinicalTrials.gg

Program

CKD-843

A development code. Also written as “CKD-843 dose#1”, “CKD-843 dose#2” and “CKD-843 A 45mg(Multiple dose)”.

Its studies are mostly in Alopecia, led by Chong Kun Dang Pharmaceutical.

Furthest: phase 3, since Apr 1, 20253 company-led studies, 1 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chong Kun Dang Pharmaceutical31 open or runningphase 3since Apr 1, 2025Mar 16, 2021Sep 30, 2027phase 3 · NCT06916793

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 16, 2021First study: phase 1 study in AlopeciaFirst studyNCT04805606 · 40 enrolled · Korea, Republic of
  2. Oct 18, 2022Phase 1 study in AlopeciaNCT05587699 · 41 enrolled · Korea, Republic of
  3. Apr 1, 2025Phase 3 study in AlopeciaNCT06916793 · 288 planned · South Korea

Ahead

  1. Sep 30, 2027Primary completion: phase 3 study in AlopeciaNCT06916793

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06916793Alopecia · South Korea3RecruitingSep 30, 2027288
NCT05587699Alopecia · Korea, Republic of1CompletedSep 15, 202341
NCT04805606Alopecia · Korea, Republic of1CompletedDec 24, 202140

How it is read

Names in the registry

  • “CKD-843 dose#1”, 1 entry
  • “CKD-843 dose#2”, 1 entry
  • “CKD-843 A 45mg(Multiple dose)”, 1 entry
  • “CKD-843 A 45mg”, 1 entry
  • “CKD-843 A 55mg(Multiple dose)”, 1 entry

Codes read as this program: CKD843.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.